September 10, 2019
March 1, 2021 | The Street
Senior Director of ML Strategies Aaron L. Josephson participated in a Q&A interview with The Street about what to expect from the U.S. Food and Drug Administration (FDA) under the Biden Administration, potential picks to head the agency, and emergency-use authorizations.
January 21, 2021 | Inside Health Policy
Senior Director of ML Strategies Aaron Josephson was quoted in Inside Health Policy on the Biden administration’s plans to reverse several Trump administration regulatory-focused executive orders, including two last-minute executive orders from the Trump administration on accountability in agency rulemaking and criminal penalties for violating certain agency regulations.
January 5, 2021 | American Health Law Association
Mintz Member M. Daria Niewenhous co-authored an American Health Lawyers Association (AHLA) Business Law and Governance Practice Group Briefing that featured a Q&A discussion with two strategic communications and media experts, including Senior Vice President, Strategic Communications of ML Strategies Nancy J. Sterling, APR, Fellow PRSA, offering insights on best practices for proactive and reactive media communications for healthcare organizations.
January 5, 2021 | Bloomberg Law
Vice President of ML Strategies Christian Fjeld was quoted in an article published by Bloomberg Law on how the Internet of Things Cybersecurity Improvement Act of 2020 may impact the industry due to the government’s purchasing power.
December 8, 2020 | Westlaw
In Thomson Reuters’ Westlaw, Vice President of ML Strategies Christian Fjeld was quoted on the Internet of Things (IoT) Cybersecurity Improvement Act of 2020, which establishes security standards for IoT devices owned or controlled by the federal government and was recently signed into law by President Trump, and its potential “spillover effects” into the private sector.
November 25, 2020 | Medtech Insight
In an article published by Medtech Insight, Senior Director of ML Strategies Aaron Josephson provided commentary on a recent proposal from the U.S. Department of Health and Human Services (HHS) to review regulations every 10 years and its potential impact on the medical device industry.